Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1 - Takeaways - MDSpire

Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1

  • By

  • Junseok Jeon

  • Youngmin Yoon

  • Kyungho Lee

  • Heasil Moon

  • Jung Eun Lee

  • Ghee Young Kwon

  • Wooseong Huh

  • Hye Ryoun Jang

  • June 24, 2026

  • 0 min

Share

  • 1

    The study enrolled 202 adults with biopsy-proven IgA nephropathy (IgAN) from 2010 to 2020 to identify prognostic biomarkers for immunosuppressive therapy.

  • 2

    A good prognosis was defined as a ≥50% reduction in urine protein-to-creatinine ratio or <0.5 g/g with preserved kidney function one year post-biopsy.

  • 3

    Among participants, 59.4% had a good prognosis, showing significantly lower risk of end-stage kidney disease over a 10-year follow-up.

  • 4

    Higher serum TGF-β1 and lower serum MCP-1 levels independently predicted good prognosis in patients receiving immunosuppressive therapy.

  • 5

    Intrarenal CD20+ cell infiltration was identified as a predictor of poor prognosis in patients receiving only supportive care.

Original Source(s)

Biomarkers predicting good prognosis among patients receiving immunosuppressive treatment in IgA nephropathy: the promising role of serum TGF-β1 and MCP-1

  • by Junseok Jeon, Youngmin Yoon, Kyungho Lee, Heasil Moon, Jung Eun Lee, Ghee Young Kwon, Wooseong Huh, Hye Ryoun Jang

  • June 24, 2026

Related Content

ASCO 2026: A New Way to Track HPV Cancer

A head-to-head comparison of ctDNA and ctHPV DNA reveals complementary insights into treatment response and recurrence risk

Editorial: Precision oncology: integrating molecular mechanisms, organoid models, and omics technologies for personalized cancer care

The Culture Clash that Shaped Me

Sitting Down With... Cristina Magi-Galluzzi, Chair of the University of Alabama at Birmingham Department of Pathology, and President of USCAP